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harmacogenetic testing for certain drug:gene pairs (eg, abacavir and HLAB5701) represents some of the clearest examples where genetic testing can markedly improve drug safety. Such examples where an adverse drug reaction is largely controlled by a single allelic variant are currently limited. Instead, most adverse drug reactions are complex traits where the impact of individual genetic variants is modest. Despite these limitations, pharmacogenetic testing may still have value from the perspective of patient, provider, and clinical outcomes.
Hydroxymethylglutaryl-Coenzyme A reductase inhibitors (or statins) are widely prescribed to lower LDLc (low-density lipoprotein cholesterol) and to prevent cardiovascular events. 1 The overall low toxicity of statins is undisputed based on evidence from numerous placebocontrolled randomized clinical trials. 2 However, statinassociated muscular symptoms (SAMS) are common in general practice affecting 5% to 15% of patients [3] [4] [5] [6] and the majority are not associated with elevations in CK (creatine kinase). 3 The causal role of statins in the development of many SAMS cases has been questioned. 7 However, SAMS is frequently cited by patients as a primary reason for statin discontinuation [8] [9] [10] [11] [12] and is associated with higher cardiovascular morbidity. 13, 14 Therefore, from a patient and provider perspective, SAMS is a significant barrier to reducing cardiovascular risk.
Genetic contributions to SAMS have been identified. A genome-wide association study of severe, but rare, simvastatin-associated myopathy identified a common, reduced function variant (rs4149056 also referred to as *5, *15, and *17 which all contain the C risk allele) in the solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene. 15 This association has been extended to statin myalgia 16 and premature statin discontinuation. 16, 17 The risks for SAMS with SLCO1B1*5 vary based on the type and dose of statin with the most consistent effects for simvastatin 18 (at low, 16 intermediate, 17 and high dosages 15 ), potential effects for atorvastatin, [18] [19] [20] and minimal effects observed for pravastatin 16 or rosuvastatin. 21 Based on these findings the Clinical Pharmacogenetics Implementation Consortium recommends avoiding high dose simvastatin in *5 carriers and instead recommends alternative statin therapy or low-dose simvastatin. 22 Based on these data, several US centers have implemented SLCO1B1*5 pharmacogenetic testing, [22] [23] [24] and testing for this variant is commercially available. 25 However, robust, prospective data defining the risks and benefits of SLCO1B1 pharmacogenetic testing are unavailable. In a prior nonrandomized trial, we demonstrated that delivery of SLCO1B1*5 genotype informed statin therapy was associated with a higher proportion of patients reporting statin use in the year after testing compared with concurrent controls, 26 suggesting that statin adherence or prescribing may be improved. Therefore, we pursued the hypothesis that compared with a strategy that does not incorporate genetic testing, delivery of SLCO1B1*5 pharmacogenetic information improves statin adherence, prescribing, and LDLc. To test these hypotheses, we utilized multiple, complementary approaches, including a randomized clinical trial.
METHODS
Full methods can be found in the Data Supplement. The authors declare that all data used to support analyses about the randomized clinical trial are available as an anonymized data set within the Data Supplement. Data supporting analysis of the commercial laboratory data will not be made available. The GIST trial (Genotype Informed Statin Therapy) protocol and statistical analysis plan are available in the Data Supplement. The Duke University Medical Center Institutional Review Board and the United States Air Force Human Research Protection Official approved the GIST trial. In addition, the Food and Drug Administration evaluated the intervention of SLCO1B1*5 GIST and determined it a nonsignificant risk device study and that an investigational device exemption was not required. The Duke University Medical Center Institutional Review Board determined that the analysis of Boston Heart Diagnostics laboratory data were research not involving human subjects.
RESULTS

GIST Trial
The flow of patients through the clinical trial is in Figure 16, 2015 . We experienced slower than anticipated recruitment primarily because many patients identified through the electronic health record did not meet inclusion criteria, and many of those that did were no longer considered eligible for statin therapy by their primary care providers. In July 2015, because of the delays in recruitment, the enrollment period was extended, and a decision to truncate the 8-month follow-up visit for patients recruited between August and October 2015 was made without any interim analyses being performed. This decision resulted in the final 29 patients only being eligible for 3-month follow-up data. Baseline characteristics of the participants are outlined in Table. Aside from female sex, which was more common in the UC arm, arms were balanced.
The median time to delivery of SLCO1B1*5 genotype informed or control recommendations into the electronic health record for statin reinitiation was 6 days. The *5 allele frequency in the entire study population was 25% and higher than expected for Europeans (minor allele frequency=16.5%, P=0.008). Adherence to the intervention was assessed by the proportion of SLCO1B1*5 carriers prescribed rosuvastatin, pravastatin, or fluvastatin versus other statins. Participants who carried SLCO1B1*5 and were allocated to disclosure of their genotype received a numerically higher proportion of rosuvastatin, pravastatin, or fluvastatin prescriptions compared with SLCO1B1*5 carriers in the control arm (92% versus 67%, P=0.24).
Delivery of SLCO1B1*5 Genetic Test Results and Statin Adherence
At the 3-month follow-up time point, 62 out of 159 (39%) reported statin utilization and completed the Morisky Medication Adherence Scale (MMAS). There was no difference in patient-reported adherence to statin therapy in the GIST versus control (MMAS, 6.8±1.5 versus 6.9±1.6, P=0.96). At 8 months, 50 out of 159 (31%) reported utilizing statins and completed the MMAS, and there was no difference (MMAS, 6.8±1.7 versus 7.1±1.3, P=0.57) between arms.
Statin Reinitiation
The proportion of patients who self-reported receiving a statin prescription between randomization and 3 months was higher in patients allocated to GIST versus control (41/74 [55.4%] versus 27/71 [38.0%]; odds ratio, 2.0; 95% CI, 1.04-3.9; P=0.037; Figure 2 ) with no differences in statin reinitiation between 4 and 8 months after randomization (6.5% versus 7.1%; odds ratio, 1.1; 95% CI, 0.3-4.9; P=0.88). The average LDLc lowering potency of the prescribed statin and dosage was no different between groups (Figure I in the Data Supplement).
Cholesterol
LDLc was lower in the intervention group compared with control at 3 months ( Figure 3A ; 131.9±42.0 versus 144.4±43.0; baseline LDLc adjusted P=0.05) with a similar, but nonsignificant, direction at 8 months (128.6±37.9 versus 141.0±44.4, P=0.12; Figure 3D ). In an analysis of LDLc over time using a mixed-effects model, however, the effect of GIST on LDLc was not significant (P value=0.22). Analyses of total and non-HDLc (high-density lipoprotein cholesterol) showed similar differences between groups as LDLc ( Figure 3B and 3C) with no differences in HDLc and triglycerides ( Figure IIA and IIB in the Data Supplement), consistent with the effects of statins on cholesterol levels.
SLCO1B1 genotype data were available (but not disclosed) to the UC arm during the trial. We found a significant treatment interaction with SLCO1B1*5 carrier status (mixed-effects P value for randomization×geno Per protocol, participants randomized to the control arm were returned their SLCO1B1 pharmacogenetic test results after all study related surveys and cholesterol testing was completed. In a prespecified analysis, we compared the change in LDLc from the last trial visit to that obtained during follow-up by gathering LDLc from the EHR (available in 34% versus 36% in intervention versus control arms, respectively). Post-trial and compared with those in the intervention arm who had already received their genetic test results, control arm participants had an additional drop in their LDLc after receiving their SLCO1B1*5 genetic test results ( Figure 5 ; mean change in LDLc from last within trial to post-trial, −14.9 mg/dL±37.8 versus +9.0 mg/dL±37.3, P=0.03).
Survey Outcomes
To explore additional effects of GIST, we surveyed patients for their diet, physical activity, and perceptions of statin therapy. There a trend toward improvement in statin perceptions as assessed by the Beliefs in Medication Questionnaire Necessity-Concerns Differential (Figure III in the Data Supplement; mixed-effects regression P value=0.06) in patients randomized to GIST and no difference in other survey measures (data not shown).
Trial Safety
There were 11 adverse events during the study (5 in the intervention versus 6 in the UC arm). Of these, 1 was designated as a severe, statin-related adverse event (elevation in liver function tests) in the UC arm. 
Observational Commercial Laboratory Data
To validate the effects of delivering SLCO1B1 GIST on LDLc in a general population, we used commercial laboratory data. Among the 143 757 patients that met our inclusion criteria, 92 271 received SLCO1B1 genetic testing as part of their initial testing and had GIST recommendations returned to their providers. On average, patients had 2.9±1.5 LDLc measurements over a period of 14.6±10.1 months. Patients who were tested were younger and more likely to be female, have cardiovascular disease, prediabetes, and not be prescribed lipid-lowering therapy (Table II in the Data Supplement). After 1:1 propensity matching, 1907 patients who received SLCO1B1 testing were similar to those who did not with the exception of female sex (Table III in 
Comparison of Randomized Trial Versus Observational Effects on LDLc
We qualitatively compared the age, sex, and baseline LDLc adjusted change in LDLc over time between studies. Compared with trial participants, patients receiving commercial laboratory SLCO1B1 testing had smaller reductions in LDLc (Figure 7) . Furthermore, in patients who were disclosed their SLCO1B1 genotype, carriers who received their test results through the GIST trial had a larger reduction in LDLc compared those through a commercial laboratory (Figure 7 ).
DISCUSSION
Pharmacogenetic testing utilizes a patient's genome to inform pharmacotherapy. The benefits of incorporating pharmacogenetic information as part of prescribing may have benefits beyond maximizing risk:benefit of a given drug and may also include improvements in medication perceptions and adherence. We used SLCO1B1 GIST as a model to define the potential benefits of delivering pharmacogenetic information from various perspectives and data sources. In a prospective randomized controlled trial, we found that compared with UC, addressing statin toxicity through pharmacogenetic testing (1) did not affect self-reported statin adherence, (2) doubled the number of new statin prescriptions, (3) lowered LDLc, particularly in SLCO1B1*5 carriers, and (4) may have improved statin perceptions. The trial findings of the impact of genetic testing on LDLc lowering were validated in 2 observational analyses where patients originally allocated to UC crossed over to receiving their pharmacogenetic test results and in a commercial testing laboratory data set. In conclusion, the pragmatic delivery of SLCO1B1 GIST lowers LDLc but not self-reported statin adherence.
The primary outcome of this study was self-reported adherence to statins based on the results of a prior, nonrandomized pilot study of GIST. 26 In the current study, delivery of SLCO1B1*5 was associated with a higher proportion of patients reporting statin reinitiation, thus validating the prior work; however, MMAS scores were no different. This apparent lack of effect on patient behavior is similar to results from studies disclosing genetic disease risk variants for type II diabetes mellitus. In these prior studies, delivery of genetic risk information may improve disease risk perceptions 27 though did not translate into benefits in medication-taking behavior. 28, 29 By addressing the perceived and real risks of SAMS, GIST targets an important cause of statin nonadherence that we hypothesized would translate into improved statin adherence. Although we improved patients' perceptions of statin's risks versus benefits ( Figure III in the Data Supplement), which we speculate allowed a higher proportion of GIST participants to agree to statin reinitiation, the subsequent ability of patients to adhere with statin therapy was no different using a measure of self-reported adherence. The proportion that reinitiated statins was lower than anticipated (39% versus 60%); however, we do not think the lack of association was because of reduced power. The absolute difference in MMAS was 0.1 points (95% CI, −1.0 to 0.73) and clinically significant differences likely require changes of at least 2 points. Therefore, although a larger proportion that restarted statins and large sample sizes may increase the precision of our estimate of an effect, they are unlikely to alter our conclusion that this intervention leads to a clinically significant improvement in self-reported statin adherence. One reason our intervention did not improve adherence maybe because it was focused only on side effects and left other barriers to adherence unaddressed. Another is that the intervention was delivered once without any scheduled, subsequent followup about genetic test results because our goal was to introduce genetic test results into the routine workflow of primary care physicians. Instead, nurse-led interven- tions that emphasize cardiovascular risk and multifactor risk reduction through multiple follow-up visits may be more effective in improving statin adherence, 30 though are costly and difficult to implement. Communication of genetic information about cardiovascular risk 31 or statin efficacy 32 in addition to statin toxicity may be more relevant for improving statin adherence. Last, self-reported adherence has known limitations, and other measures of medications adherence, such as electronic monitoring devices or prescription refills may be a more accurate measure. Despite the lack of benefit on self-reported adherence, there was no evidence of harm. Therefore, although delivery of SLCO1B1 genetic data improved statin reinitiation and perceptions, it did not improve a measure of self-reported statin adherence.
The primary pharmacological effect of statin therapy is to reduce LDLc, which is the primary mechanism by which statins reduce cardiovascular risk.
1 Using 3 complementary approaches, we provide evidence that delivery of SLCO1B1*5 genetic information improves LDLc. First, during the trial, LDLc was lowered by 20.2 mg/dL on average in patients randomized to receiving their genetic test results. Second, control arm participants who crossed over to the intervention post-trial had a 14.9 mg/dL drop in LDLc compared with a slight increase in the intervention arm. Using observational data from a commercial testing laboratory, patients whose physicians ordered SLCO1B1 testing had a lower LDLc during follow-up compared with propensity score-matched controls that were smaller in magnitude compared with trial participants but in the same direction. The concordance of these findings provides additional evidence that delivery of SLCO1B1*5 genotype information improves LDLc. The magnitude of LDLc lowering in trial participants was less than what would be expected with low-intensity statin therapy though is similar to that achieved with ezetimibe.
1 Future implementation studies can consider the costs of implementing genetic testing for SLCO1B1 (as a stand-alone versus panel based test) versus ezetimibe or other nonstatin therapies to achieve LDLc lowering in this patient population. Based on the LDLc lowering results, future studies could also examine the use of SLCO1B1 testing to improve appropriate statin prescribing in patients not on statins who meet criteria for therapy.
Although our study was not designed to systematically identify sources of variation that contribute to treatment effect, we explored for differences with respect to SLCO1B1 carrier status. In trial participants, we found that the effect of delivering pharmacogenetic information on LDLc varied significantly as a function of carrier status (interaction P value=0.048) such that carriers had a larger decrease in LDLc with the intervention versus noncarriers. We speculate that delivery of an actionable genetic test result that recommends a specific action that addresses the genetic finding is more effective than delivering a negative genetic test result that provides reassurance. Our results would indicate that with respect to statins, carriers of reduced SLCO1B1 function alleles may benefit from having their test results used as part of their clinical care, whereas noncarriers may see minimal benefit (or harm). By extension, the frequency of reduced function alleles in SLCO1B1 within a population could be used as a proxy for the potential benefits of SLCO1B1 genotyping in that population.
The GIST trial incorporated a series of pragmatic, design features to enable translation to clinical practice. For example, extensive provider training was not required, and the single 1-hour informational session for providers was optional. Second, aside from providing informed consent, there was minimal interaction with the study staff. Providers were encouraged to reinitiate statins based on their best clinical judgment and if agreeable to their patients by using existing, routine clinical workflows for prescribing and laboratory testing. Third, communication of genotype (or control) results was done through simple 1-page portable document format delivered through the EHR to providers and participants. Although each of these features allowed for pragmatic delivery, future studies can evaluate the extent to which enhanced patient and provider training, education, and engagement can improve trial results. The main limitation of our intervention is that since the time the study was designed, there has been more evidence 18 around atorvastatin that calls into question the risk of SAMS in SLCO1B1*5 carriers despite their known, elevated atorvastatin concentrations 20 and known correlation with atorvastatin metabolites and SAMS. 19 In both the GIST trial and commercial testing data, SLCO1B1*5 carriers are not recommended to take atorvastatin. Therefore, future iterations of this intervention should account for the level of uncertainty around the risk for SAMS and atorvastatin versus simvastatin.
The overall goal of pharmacogenomics is to improve outcomes of drug therapy through use of a patient's individual genomic characteristics and is often lauded as the low hanging fruit of precision medicine. Key barriers to translating pharmacogenetics into clinic practice are understanding the benefits, harms, and magnitude of effects. We used a series of complementary approaches, including a randomized clinical trial, to demonstrate that the benefits of delivering SLCO1B1 GIST are likely related to reinitiating statins and lowering LDLc without significant harms. Although the magnitude of effects on LDLc is, on average, modest, they seem to be in enhanced in carriers and in settings where patients and providers receive have an opportunity to discuss GIST test results.
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